PIA
LRMR icon

Piedmont Investment Advisors’s Larimar Therapeutics LRMR Stock Holding History

Piedmont Investment Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33
Closed -$4K – 1735
2018
Q2 		$4K Buy
+33
New +$2.8K ﹤0.01% 2247

Other funds holding LRMR

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Piedmont Investment Advisors's LRMR Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Larimar Therapeutics (LRMR) in Q3 2018, closing a stake of 33 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in LRMR in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 89 funds tracked by Wall St. Rank hold LRMR as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Larimar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 33 Larimar Therapeutics shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Larimar Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Larimar Therapeutics position peaked at $4K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.